Literature DB >> 27577725

Bone imaging in hypoparathyroidism.

B C Silva1,2, M R Rubin3, N E Cusano3, J P Bilezikian3.   

Abstract

Hypoparathyroidism (HypoPT) is an uncommon endocrine disorder characterized by chronic deficiency or absence of parathyroid hormone (PTH), which leads to a profound reduction in bone remodeling. Subjects with HypoPT typically have bone mineral densities (BMDs) by dual-energy X-ray absorptiometry (DXA) above average at all skeletal sites, with greatest scores observed at the lumbar spine. Trabecular bone score (TBS), an indirect measure of bone microarchitecture, also appears to be normal in HypoPT. By peripheral quantitative computed tomography (pQCT) of the radius, volumetric BMD at cancellous and cortical compartments, as well as cortical area and thickness, are greater in hypoparathyroid subjects than in controls. The use of high-resolution pQCT (HRpQCT) confirmed the increase in cortical volumetric BMD but demonstrated reduced cortical thickness, associated with lower cortical porosity in HypoPT. Trabeculae tend to be more numerous but thinner in hypoparathyroid subjects. It is not clear whether these structural and the dynamic skeletal abnormalities in HypoPT affect bone strength or fracture risk. Treatment of HypoPT with PTH leads to improvement in bone remodeling rate, variable changes in bone density, and a transient increase in estimated bone strength. The effect of PTH therapy on fracture risk remains unknown. This article reviews skeletal involvement and the effect of PTH treatment in patients with HypoPT, as assessed by DXA, TBS, QCT, and HRpQCT. Data on bone strength and fracture risk in HypoPT are also reviewed here.

Entities:  

Keywords:  Bone microarchitecture; Bone mineral density; Bone strength; Fracture risk; Hypoparathyroidism; PTH

Mesh:

Substances:

Year:  2016        PMID: 27577725     DOI: 10.1007/s00198-016-3750-0

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  38 in total

Review 1.  Clinical practice. Hypoparathyroidism.

Authors:  Dolores Shoback
Journal:  N Engl J Med       Date:  2008-07-24       Impact factor: 91.245

2.  Hypoparathyroidism in the adult: epidemiology, diagnosis, pathophysiology, target-organ involvement, treatment, and challenges for future research.

Authors:  John P Bilezikian; Aliya Khan; John T Potts; Maria Luisa Brandi; Bart L Clarke; Dolores Shoback; Harald Jüppner; Pierre D'Amour; John Fox; Lars Rejnmark; Leif Mosekilde; Mishaela R Rubin; David Dempster; Rachel Gafni; Michael T Collins; Jim Sliney; James Sanders
Journal:  J Bone Miner Res       Date:  2011-10       Impact factor: 6.741

3.  Parathyroid hormone therapy for hypoparathyroidism.

Authors:  Natalie E Cusano; Mishaela R Rubin; John P Bilezikian
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2014-09-10       Impact factor: 4.690

4.  Transient Increased Calcium and Calcitriol Requirements After Discontinuation of Human Synthetic Parathyroid Hormone 1-34 (hPTH 1-34) Replacement Therapy in Hypoparathyroidism.

Authors:  Rachel I Gafni; Lori C Guthrie; Marilyn H Kelly; Beth A Brillante; C Michele Christie; James C Reynolds; Nancy A Yovetich; Robert James; Michael T Collins
Journal:  J Bone Miner Res       Date:  2015-08-03       Impact factor: 6.741

5.  Long-term treatment of 12 children with chronic hypoparathyroidism: a randomized trial comparing synthetic human parathyroid hormone 1-34 versus calcitriol and calcium.

Authors:  Karen K Winer; Ninet Sinaii; James Reynolds; Donna Peterson; Karen Dowdy; Gordon B Cutler
Journal:  J Clin Endocrinol Metab       Date:  2010-04-14       Impact factor: 5.958

6.  European Society of Endocrinology Clinical Guideline: Treatment of chronic hypoparathyroidism in adults.

Authors:  Jens Bollerslev; Lars Rejnmark; Claudio Marcocci; Dolores M Shoback; Antonio Sitges-Serra; Wim van Biesen; Olaf M Dekkers
Journal:  Eur J Endocrinol       Date:  2015-08       Impact factor: 6.664

7.  Daily parathyroid hormone 1-34 replacement therapy for hypoparathyroidism induces marked changes in bone turnover and structure.

Authors:  Rachel I Gafni; Jaime S Brahim; Panagiota Andreopoulou; Nisan Bhattacharyya; Marilyn H Kelly; Beth A Brillante; James C Reynolds; Hua Zhou; David W Dempster; Michael T Collins
Journal:  J Bone Miner Res       Date:  2012-08       Impact factor: 6.741

8.  Therapy of hypoparathyroidism with intact parathyroid hormone.

Authors:  M R Rubin; J Sliney; D J McMahon; S J Silverberg; J P Bilezikian
Journal:  Osteoporos Int       Date:  2010-01-22       Impact factor: 4.507

Review 9.  Bone disease in hypoparathyroidism.

Authors:  Bart L Clarke
Journal:  Arq Bras Endocrinol Metabol       Date:  2014-07

10.  Increased vertebral morphometric fracture in patients with postsurgical hypoparathyroidism despite normal bone mineral density.

Authors:  Maira L Mendonça; Francisco A Pereira; Marcello H Nogueira-Barbosa; Lucas M Monsignore; Sara R Teixeira; Plauto Ca Watanabe; Lea Mz Maciel; Francisco Ja de Paula
Journal:  BMC Endocr Disord       Date:  2013-01-03       Impact factor: 2.763

View more
  7 in total

1.  Does parathyroid hormone control bone quality?

Authors:  Dolores Shoback
Journal:  Endocrine       Date:  2017-01-02       Impact factor: 3.633

Review 2.  Skeletal abnormalities in Hypoparathyroidism and in Primary Hyperparathyroidism.

Authors:  Barbara C Silva; John P Bilezikian
Journal:  Rev Endocr Metab Disord       Date:  2020-11-16       Impact factor: 6.514

Review 3.  Teriparatide administration by the Omnipod pump: preliminary experience from two cases with refractory hypoparathyroidism.

Authors:  Karine Aouchiche; Rachel Reynaud; Vincent Amodru; Thierry Brue; Thomas Cuny
Journal:  Endocrine       Date:  2022-01-04       Impact factor: 3.925

Review 4.  Secondary Osteoporosis and Metabolic Bone Diseases.

Authors:  Mahmoud M Sobh; Mohamed Abdalbary; Sherouk Elnagar; Eman Nagy; Nehal Elshabrawy; Mostafa Abdelsalam; Kamyar Asadipooya; Amr El-Husseini
Journal:  J Clin Med       Date:  2022-04-24       Impact factor: 4.964

5.  Clinical profile and long-term follow-up of 32 patients with postoperative permanent hypoparathyroidism.

Authors:  Leyre Lorente-Poch; Juan J Sancho; Leticia Carballo; Antonio Sitges-Serra
Journal:  Gland Surg       Date:  2017-12

6.  Severe Phenotype of APECED (APS1) Increases Risk for Structural Bone Alterations.

Authors:  Saila Laakso; Joonatan Borchers; Sanna Toiviainen-Salo; Minna Pekkinen; Outi Mäkitie
Journal:  Front Endocrinol (Lausanne)       Date:  2020-03-06       Impact factor: 5.555

Review 7.  The clinical application of high-resolution peripheral computed tomography (HR-pQCT) in adults: state of the art and future directions.

Authors:  J P van den Bergh; P Szulc; A M Cheung; M Bouxsein; K Engelke; R Chapurlat
Journal:  Osteoporos Int       Date:  2021-05-22       Impact factor: 4.507

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.